scholarly journals The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

2019 ◽  
Author(s):  
Mohammed Altyb Alshykh ◽  
Mohammed Elmujtba Adam Essa ◽  
Yousra Abdelmoniem Suleiman ◽  
Sherihan Mohammed Elkundi Osman ◽  
Mustafa Mohamed Ali Hussein ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Age Group ◽  
Second Line ◽  
Cancer Antigen 125 ◽  
First Line ◽  
Serous Adenocarcinoma ◽  
Cancer Antigen ◽  
Second Line Chemotherapy ◽  
Platinum Resistant ◽  
Line Chemotherapy

Abstract Background Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumor mostly associated with variant factors such as advance age, early menstruation and gene association. We aimed to highlight the effectiveness of the second line chemotherapy in the management of ovarian cancer patients in Sudan.Methods The data were collected from the hospital patient’s records for five years period of time, included 62 patients with ovarian cancer who is treated by the second line platinum resistant chemotherapy.Result The peak prevalence of the patients was found in Al-Gazeera state, and the least in Al-Gadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially mass disappearing, completes and continue growing tumor respectively. All patients received variant cycles of chemotherapy as fellow 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. In 50% of patients the cancer recurred after 1-2 months, 32.2% after 3-4 months and 17.8% after 5-6 months. The serous adenocarcinoma was found to be the most histological type in all the patients and the least two types were observed are cell carcinoma and serous papillary.Conclusion Our findings suggested that, Al-Gazeera state citizens were more vulnerable to resist the first line chemotherapy than others. The Sudanese patients with ovarian cancer may have better response to Gemzar.

scholarly journals The Response of Second Line Chemotherapy Platinum Resistant Ovarian Cancer in Sudan: 2013-2017

2019 ◽  
Author(s):  
Mohammed Altyb Alshykh ◽  
Mohammed Elmujtba Adam Essa ◽  
Yousra Abdelmoniem Suleiman ◽  
Sherihan Mohammed Elkundi Osman ◽  
Mutwaly Defealla Yousif Haron ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Recurrence ◽  
Disease Recurrence ◽  
Second Line ◽  
Cancer Antigen 125 ◽  
First Line ◽  
Serous Adenocarcinoma ◽  
Second Line Chemotherapy ◽  
Platinum Resistant ◽  
Line Chemotherapy

Abstract Background Ovarian carcinoma is the fifth leading cause of cancer death worldwide. The tumor mostly associated with variant factors such as advance age, early menstruation and gene association. We aimed to highlight the effectiveness of the second line chemotherapy in the management of ovarian cancer patients in Sudan. Methods The data were collected from the hospital patient’s records for five years period of time, included 62 patients with ovarian cancer who is treated by the second line platinum resistant chemotherapy. Result The peak prevalence of the patients was found in Aljazeera state, and the least in Algadarif state. Age group above 55 years was the most affected group. The vast majority of patients showed partially mass disappearing, completes and continue growing tumor respectively. All patients received variant cycles of chemotherapy as fellow 3, 6, 2, 4, 5, 1 cycle respectively. 79.4% of the patients had achieved the normal value of cancer antigen 125 (CA125) levels after the treatment. 50% of patients had 1-2 months interval time before the cancer recurrence, 32.2% had 3-4 months and 17.8% had 5-6 months before the disease recurrence. The serous adenocarcinoma was found to be the most histological type in all the patients and the least two types were observed are cell carcinoma and serous papillary. Conclusion Our findings suggested that, Aljazeera state citizens were more vulnerable to resist the first line chemotherapy than others. The Sudanese patients with ovarian cancer may have better response to Gemzar.

scholarly journals High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer

1995 ◽  
Vol 37 (1-2) ◽  
pp. 190-192 ◽  
Author(s):  
J. T. Kamphuis ◽  
M. C. Huider ◽  
G. J. Ras ◽  
C. A. H. Verhagen ◽  
I. Kateman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
High Dose ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Platinum Resistant ◽  
Line Chemotherapy

Second line chemotherapy (CT) with gemcitabine (G) and vepesid (VP16) in platinum resistant (DDP-R) advanced ovarian cancer (AOC) patients

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5082-5082
Author(s):  
M. Bruzzone ◽  
M. Mencoboni ◽  
S. Mammoliti ◽  
F. Boccardo ◽  
L. Tacchini ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Platinum Resistant ◽  
Line Chemotherapy

Do Patients With Platinum-Resistant Epithelial Ovarian Cancer Benefit From Second-line Chemotherapy?

2010 ◽  
Vol 3 (1) ◽  
pp. 36-40
Author(s):  
Kenji Hashimoto ◽  
Noriyuki Katsumata ◽  
Taizo Hirata ◽  
Kan Yonemori ◽  
Tsutomu Kouno ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Epithelial Ovarian Cancer ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Platinum Resistant ◽  
Line Chemotherapy

scholarly journals Management of neuroblastoma: a study of first- and second-line chemotherapy responses, a single institution experience

2012 ◽  
Vol 6 (1) ◽  
pp. 3 ◽  
Author(s):  
Emmad E. Habib ◽  
Amr T. El-Kashef ◽  
Ezzat S. Fahmy
Keyword(s):  
External Beam Radiotherapy ◽  
Second Line ◽  
First Line ◽  
Actuarial Survival ◽  
Term Survival ◽  
Second Line Chemotherapy ◽  
Significant Difference ◽  
Grade Malignancy ◽  
Chemotherapy Patients ◽  
Line Chemotherapy

Neuroblastoma is a high-grade malignancy of childhood. It is chemo- and radio-sensitive but prone to relapse after initial remission. The aim of the current study was to study the results of the first- and second-line chemotherapy on the short-term response and long-term survival of children, and to further describe the side effects of treatment. Ninety-five children with advanced neuroblastoma were included in the study, divided into two groups according to the treatment strategy: 65 were treated by first-line chemotherapy alone, and 30 children who were not responding or relapsed after first-line chemotherapy were treated by second-line chemotherapy. External beam radiotherapy was given to bone and brain secondary cancers when detected. Staging workup was performed before, during and after management. Response was documented after surgery for the primary tumor. Median follow up was 32 months (range 24-60 months). Chemothe rapy was continued until toxicity or disease progression occurred, indicating interruption of chemotherapy. Patients received a maximum of 8 cycles. Toxicity was mainly myelo-suppression, with grade II-III severity in 60% of the firstline and 70% of the second-line chemotherapy patients. Median total actuarial survival was nearly 51 months for the first-line chemotherapy group and 30 months for the second-line line group, with a statistically significant difference between the two groups (P<0.01).

Elevation of Neutrophil-to-Lymphocyte Ratio before First-Line Chemotherapy Predicts a Poor Prognosis for Second-Line Chemotherapy in Gastric Cancer

Oncology ◽  
2018 ◽  
Vol 96 (3) ◽  
pp. 140-146 ◽  
Author(s):  
Dai Inoue ◽  
Shuhei Sekiguchi ◽  
Wataru Yamagata ◽  
Gen Maeda ◽  
Daiki Yamada ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Poor Prognosis ◽  
Neutrophil To Lymphocyte Ratio ◽  
Second Line ◽  
First Line ◽  
Lymphocyte Ratio ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document